Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Study Completion Date

January 31, 2007

Conditions

Atopic Dermatitis

Interventions

DRUG

Alefacept

15 mg i.m. once weekly for 12 weeks

Trial Locations (1)

Inselspital Dermatology, Bern

All Listed Sponsors

collaborator

Biogen-Dompé AG

INDUSTRY

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT00376129 - Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter